Advertisement

Infusion intrathécale : médication, techniques et gestion des complications

  • Denis DupoironEmail author

Résumé

L’infusion d’antalgiques dans le liquide céphalorachidien date de la fin du XIXe siècle [1] mais il faudra attendre 1979, après la publication de la théorie du portillon1 [2], puis la découverte des récepteurs morphiniques par Pert et Snider [3], pour que les premières expériences humaines [4] mettent en évidence l’intérêt de cette technique dans le traitement de la douleur. Ensuite, la mise à disposition de pompes totalement implantables a permis de la développer considérablement au cours des vingt dernières années. Initialement, seule la morphine était utilisée par cette voie, mais au cours du temps, les associations médicamenteuses se sont largement développées.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Drasner K (2009) Spinal anaesthesia: a century of refinement, and failure is still an option. Br J Anaesth 102(6): 729–730CrossRefPubMedGoogle Scholar
  2. 2.
    Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150(3699): 971–979CrossRefPubMedGoogle Scholar
  3. 3.
    Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. Science 179(4077): 1011–1014CrossRefPubMedGoogle Scholar
  4. 4.
    Wang JK, Nauss LA, Thomas JE (1979) Pain relief by intrathecally applied morphine in man. Anesthesiology 50(2): 149–151CrossRefPubMedGoogle Scholar
  5. 5.
    Smith TJ, Staats PS, Deer T, et al. (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19): 4040–4049CrossRefPubMedGoogle Scholar
  6. 6.
    Hayek SM, Deer TR, Pope JE, et al. (2011) Intrathecal therapy for cancer and non-cancer pain. Pain physician 14(3): 219–248PubMedGoogle Scholar
  7. 7.
    Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139(2): 267–284CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Atweh SF, Kuhar MJ (1977) Autoradiographic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla. Brain Res 124(1): 53–67CrossRefPubMedGoogle Scholar
  9. 9.
    Buvanendran A (2012) Intrathecal Drug Delivery for Pain and Spasticity. ElsevierGoogle Scholar
  10. 10.
    Miljanich G, Rauck R, Saulino M (2013) Spinal mechanisms of pain and analgesia. Pain Pract 13(2): 114–130CrossRefPubMedGoogle Scholar
  11. 11.
    Friese S, Hamhaber U, Erb M, et al. (2004) The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol 39(2): 120–130CrossRefPubMedGoogle Scholar
  12. 12.
    Bernards CM (2006) Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 105(1): 169–178CrossRefPubMedGoogle Scholar
  13. 13.
    Flack SH, Anderson CM, Bernards C (2011) Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 112(2): 460–464CrossRefPubMedGoogle Scholar
  14. 14.
    Y. V (2003) Opioïdes intrathécaux. Anesthesiologie Conférences scientifiques 2(2) : 1–6Google Scholar
  15. 15.
    Ummenhofer WC, Arends RH, Shen DD, Bernards CM (2000) Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 92(3): 739–753CrossRefPubMedGoogle Scholar
  16. 16.
    Du Pen S, Du Pen A, Hillyer J (2006) Intrathecal hydromorphone for intractable nonmalignant pain: a retrospective study. Pain Med 7(1): 10–15CrossRefPubMedGoogle Scholar
  17. 17.
    Deer TR, Prager J, Levy R, et al. (2012) Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 15(5): 436–464CrossRefPubMedGoogle Scholar
  18. 18.
    Deer TR, Prager J, Levy R, et al. (2012) Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 15(5): 483–495CrossRefPubMedGoogle Scholar
  19. 19.
    Scholz A, Kuboyama N, Hempelmann G, Vogel W (1998) Complex blockade of TTX-resistant Na+ currents by lidocaine and bupivacaine reduce firing frequency in DRG neurons. J Neurophysiol 79(4): 1746–1754PubMedGoogle Scholar
  20. 20.
    van Dongen RT, Crul BJ, van Egmond J (1999) Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 15(3): 166–172CrossRefPubMedGoogle Scholar
  21. 21.
    Bianchi F, Ginggen A, Tardy Y (2008) Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia 63(9): 972–978CrossRefPubMedGoogle Scholar
  22. 22.
    Dupoiron DL-kD, Brenet O, de Bourmont S, et al. (2011) Douleur chronique cancéreuse et analgésie intrathécale : expérience de trois centres de lutte contre le cancer. Douleurs 12(3): 140–146Google Scholar
  23. 23.
    Schmidtko A, Lotsch J, Freynhagen R, Geisslinger G (2010) Ziconotide for treatment of severe chronic pain. Lancet 375(9725): 1569–1577CrossRefPubMedGoogle Scholar
  24. 24.
    Pope JE, Deer TR (2013) Ziconotide: a clinical update and pharmacologic review. Expert opinion on pharmacotherapy 14(7): 957–966CrossRefPubMedGoogle Scholar
  25. 25.
    Deer TR, Smith HS, Burton AW, et al. (2011) Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Phys 14(3): E283–312Google Scholar
  26. 26.
    Prager J, Deer T, Levy R, et al. (2014) Best Practices for Intrathecal Drug Delivery for Pain. Neuromodulation 17(4): 354–72CrossRefPubMedGoogle Scholar
  27. 27.
    Mohammed SI, Eldabe S, Simpson KH, et al. (2013) Bolus intrathecal injection of ziconotide (Prialt(R)) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation 16(6): 576–581CrossRefPubMedGoogle Scholar
  28. 28.
    Aprili D, Bandschapp O, Rochlitz C, et al. (2009) Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis. Anesthesiology 111(6): 1346–1355CrossRefPubMedGoogle Scholar
  29. 29.
    Hassenbusch SJ, Portenoy RK, Cousins M, et al. (2004) Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery--report of an expert panel. J Pain Symptom Manage 27(6): 540–563CrossRefPubMedGoogle Scholar
  30. 30.
    Dupoiron D, Bore F, Lefebvre-Kuntz D, et al. (2012) Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Phys 15(5): 395–403Google Scholar
  31. 31.
    Alicino I, Giglio M, Manca F, et al. (2012) Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 153(1): 245–249CrossRefPubMedGoogle Scholar
  32. 32.
    Dupoiron D, Richard H, Chabert-Desnot V, et al. (2014) In Vitro Stability of Low-Concentration Ziconotide Alone or in Admixtures in Intrathecal Pumps. Neuromodulation (Epub ahead of print)Google Scholar

Copyright information

© Springer-Verlag Paris 2014

Authors and Affiliations

  1. 1.Département d’anesthésie-douleurInstitut de cancérologie de l’Ouest — Paul PapinAngersFrance

Personalised recommendations